H.I.G. Capital Buys Back Vantage Specialty Chemicals

(c) SFIO CRACHO/Shutterstock
(c) SFIO CRACHO/Shutterstock

US-headquartered private equity group H.I.G. Capital has signed an agreement to acquire Vantage Specialty Chemicals Holdings, buying back a business it sold to The Jordan Company (TJC) five years ago.

New York-based investment group TJC will retain a minority stake in the new deal. Financial terms of the transaction were not disclosed but industry sources are reported to put the purchase price at $1 billion.

Based in Chicago, Illinois, Vantage was initially formed in early 2008 through H.I.G’s acquisition of the US oleochemicals business of Croda International for around $92 million. Vantage then acquired two downstream specialty ingredients businesses before subsequently being bought by TJC in January 2012.

Currently, Vantage operates six manufacturing facilities throughout the US with laboratories and offices in 14 countries across the US, Latin America, South Africa, Europe and Asia.

Keval Patel, H.I.G.’s managing director, commented: “The company’s diverse product portfolio, customer base and geographic presence uniquely position it to capitalize on growth opportunities within the global specialty ingredients market.”

Vantage’s existing management team will remain in place. The transaction, which will be the 15th chemicals acquisition for H.I.G. since 2008, is expected to close this month, subject to the usual conditions.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

most read